Hypochlorous Acid in Non-Surgical Periodontal Therapy
The Effect of Hypochlorous Acid in the Non-Surgical Treatment of Stage I and Stage II Periodontitis
2 other identifiers
interventional
44
1 country
1
Brief Summary
Periodontitis is a chronic inflammatory disease associated with dental plaque and characterized by the progressive destruction of the tooth-supporting tissues. The principal features of periodontitis include clinical attachment loss (CAL), alveolar bone loss, periodontal pocket formation, gingival bleeding, and the subsequent loss of periodontal tissue support. The current gold standard for the management of periodontal disease comprises oral hygiene instruction (OHI), non-surgical periodontal therapy (NSPT), periodontal surgery when indicated, and supportive periodontal therapy (SPT). In addition, various antimicrobial agents are used as adjuncts to periodontal treatment. One such agent, hypochlorous acid (HOCl), is a potent antimicrobial with high affinity against Gram-negative bacteria within the subgingival biofilm. Hypochlorous acid is commercially available in mouthwash and spray formulations, which patients may use as adjunctive therapies following periodontal treatment. In the present project, hypochlorous acid will be applied by the clinician using a dental device during periodontal treatment in a clinical setting. Changes in both clinical and biochemical outcomes, including high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), antistreptolysin O (ASO), and oncostatin M (OSM), will be recorded and compared with those obtained following conventional periodontal treatment performed using purified water. The novelty of the proposed study lies in the first-time use of hypochlorous acid as an irrigant in place of purified water during scaling and root planing (SRP), with the aim of evaluating its effects on both clinical and biochemical parameters. This project is expected to attract the attention of researchers investigating the treatment of periodontitis and may facilitate publication in high-impact international peer-reviewed journals as well as presentation at prestigious scientific congresses. Furthermore, it will contribute to the training of qualified researchers in periodontology and support the completion of a doctoral dissertation. The findings may also provide preliminary data for future studies aimed at developing hypochlorous acid-based adjunctive therapeutic approaches for the management of periodontitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 12, 2026
CompletedFirst Submitted
Initial submission to the registry
June 14, 2026
CompletedFirst Posted
Study publicly available on registry
July 17, 2026
CompletedJuly 17, 2026
July 1, 2026
7 months
June 14, 2026
July 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Clinical Attachment Level (CAL)
Assessment of clinical attachment level (CAL), measured in millimeters, as an indicator of periodontal tissue healing.
Baseline, 1 month and 3 months
Probing Pocket Depth (PPD)
Assessment of probing pocket depth (PPD), measured in millimeters, to evaluate clinical periodontal healing.
Baseline, 1 month and 3 months
Plaque Index (PI)
Assessment of dental plaque accumulation.
Baseline, 1 month and 3 months
Bleeding on Probing (BOP)
Assessment of gingival bleeding following periodontal probing.
Baseline, 1 month and 3 months
Secondary Outcomes (4)
C-Reactive Protein (CRP)
Baseline, 1 month, and 3 months
High-Sensitivity C-Reactive Protein (hs-CRP)
Baseline, 1 month and 3 months
Oncostatin M (OSM)
Baseline, 1 month and 3 months
Antistreptolysin O (ASO)
Baseline, 1 month and 3 months
Study Arms (2)
Scaling and Root Planing (SRP) with Hypochlorous Acid
EXPERIMENTALParticipants will undergo scaling and root planing (SRP) using hypochlorous acid.
Scaling and Root Planing (SRP) with Purified Water
ACTIVE COMPARATORParticipants will undergo scaling and root planing (SRP) using an ultrasonic device with purified water.
Interventions
Scaling and root planing (SRP) will be performed using an ultrasonic device with a hypochlorous acid solution.
Scaling and root planing (SRP) will be performed using an ultrasonic device with purified water.
Eligibility Criteria
You may qualify if:
- Individuals aged 18 to 65 years.
- Systemically healthy individuals.
- Diagnosis of Stage I or Stage II periodontitis according to the 2017 Classification of Periodontal Diseases.
- Probing pocket depth (PPD) ≤5 mm and clinical attachment loss (CAL) ≤4 mm.
- Presence of a sufficient number of teeth for periodontal evaluation.
- Willingness to participate and ability to provide written informed consent.
You may not qualify if:
- Patients with contraindications to the use of ultrasonic instrumentation.
- Pregnant or lactating women.
- Patients receiving anti-inflammatory or antibiotic therapy.
- Patients with systemic diseases or medical conditions.
- Patients receiving continuous medication for any medical condition.
- Patients who have undergone periodontal treatment within the previous 6 months.
- Patients presenting with acute dental pain (e.g., pulpitis or apical/periodontal abscess).
- Individuals who smoke or consume alcohol.
- Presence of fewer than 15 teeth.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Dentistry, Atatürk University
Erzurum, Erzurum, Turkey (Türkiye)
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- The clinical outcome assessor will be blinded to group allocation. The clinician performing the intervention will be aware of the assigned treatment; however, participants will not be explicitly informed of their group allocation.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 14, 2026
First Posted
July 17, 2026
Study Start
October 9, 2025
Primary Completion
May 15, 2026
Study Completion
June 12, 2026
Last Updated
July 17, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared due to confidentiality and privacy considerations. As this is a single-center study involving a limited number of participants, no formal data-sharing plan has been established.